LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its...
Media ReleaseCOPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong...
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
OvaStem® Demonstrates Strong Long-Term Efficacy with No Safety Concerns, Backed by Pending Orphan Drug Designation for AlloStem®PHOENIX, Feb. 20, 2025...
SAN FRANCISCO and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor...
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News...
Brings over 30 years of life sciences industry experienceCo-led the McKinsey Global Life Sciences practice Bergen, Norway, February 12, 2025...
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to...
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will...
Expanding market reach to drive organic revenue growth without equity dilutionCollaborating with AI-driven health assessments and customized pharmacy solutions to...
Gad Soffer Joins as Chief Business Officer and Richard Silva, Ph.D., as Senior Vice President of Technical OperationsNEW YORK, Feb....
Dr. Hege joins the Board as EvolveImmune prepares to enter the clinic in mid-2025 with EVOLVE104, its lead trispecific T...
Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology...
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) --...
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology...
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE...